Gadolinium Dimeglumine as a Contrast Agent for Digital Subtraction Angiography: in Vitro Hounsfield Unit Measurement and Clinical Efficacy.
10.3349/ymj.2003.44.1.138
- Author:
Man Deuk KIM
1
;
Hyun KIM
Author Information
1. Department of Diagnostic Radiology, Bundang CHA General Hospital, College of Medicine, Pochon CHA University, 351 Yatap-dong, Bundang-gu, Sungnam-si, Kyonggi-do, Korea. mdkim@cha.ac.kr
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Gadolinium;
hounsfield unit;
DSA
- MeSH:
Angiography, Digital Subtraction/*methods;
*Contrast Media/adverse effects;
Feasibility Studies;
Gadolinium DTPA/adverse effects/*diagnostic use;
Human;
Safety
- From:Yonsei Medical Journal
2003;44(1):138-142
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to evaluate the feasibility and safety of using gadolinium-chelates for digital subtraction angiography (DSA) in patients with contraindications to iodinated contrast material, and to assess the clinically effective concentration of gadolinium (Gd). Gadopentetate dimeglumine and iopromide were used in density measurements. Using 20 mL disposable syringes, serial dilutions of Gd and iopromide with saline were performed. Computed tomography scanning was done and the attenuation of each was recorded as mean Hounsfield units using region of interest analysis. Clinical trials were done in twelve patients with the following types of angiogram or intervention: hemodialysis access, percutaneous biliary drainage, percutaneous nephrostomy, cerebral angiography and transarterial chemoembolization (TACE) in hepatocellular carcinoma. The density of 1 : 1 diluted Gd was nearly equal to that of 1 : 4 dilution of iopromide, and that of pure Gd was similar to or less than that of 1 : 1 dilution of iopromide. Serum creatinine level was not elevated in any of the patients. Gd is a safe alternative agent in patients with contraindications to iodinated contrast materials. Pure Gd without dilution is the most clinically useful concentration.
